MA53388A - Inhibiteurs d'inflammasome nlrp3 - Google Patents
Inhibiteurs d'inflammasome nlrp3Info
- Publication number
- MA53388A MA53388A MA053388A MA53388A MA53388A MA 53388 A MA53388 A MA 53388A MA 053388 A MA053388 A MA 053388A MA 53388 A MA53388 A MA 53388A MA 53388 A MA53388 A MA 53388A
- Authority
- MA
- Morocco
- Prior art keywords
- inflammasome
- nlrp3 inhibitors
- nlrp3
- inhibitors
- Prior art date
Links
- 108010034143 Inflammasomes Proteins 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185580 | 2018-07-25 | ||
| EP19175246 | 2019-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53388A true MA53388A (fr) | 2021-06-02 |
Family
ID=67989037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053388A MA53388A (fr) | 2018-07-25 | 2019-07-23 | Inhibiteurs d'inflammasome nlrp3 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210308140A1 (ja) |
| EP (1) | EP3827008B1 (ja) |
| JP (1) | JP2021532124A (ja) |
| KR (1) | KR20210038877A (ja) |
| CN (1) | CN112424207B (ja) |
| AU (1) | AU2019309727B2 (ja) |
| BR (1) | BR112021000964A2 (ja) |
| CA (1) | CA3103943A1 (ja) |
| CL (1) | CL2021000191A1 (ja) |
| CO (1) | CO2021000537A2 (ja) |
| CR (1) | CR20210045A (ja) |
| CU (1) | CU20210009A7 (ja) |
| DO (1) | DOP2021000019A (ja) |
| EC (1) | ECSP21004787A (ja) |
| IL (1) | IL280336A (ja) |
| JO (1) | JOP20210017A1 (ja) |
| MA (1) | MA53388A (ja) |
| MX (1) | MX2021000925A (ja) |
| PE (1) | PE20210406A1 (ja) |
| PH (1) | PH12021550166A1 (ja) |
| SG (1) | SG11202012321PA (ja) |
| WO (1) | WO2020021447A1 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330054A1 (en) * | 2020-03-31 | 2023-10-19 | Olatec Therapeutics Llc | Method for preventing or treating lung infection and lung inflammation |
| JP2023522016A (ja) | 2020-04-15 | 2023-05-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３インフラマソーム経路の阻害剤としてのピラゾロ［１，５－ｄ］［１，２，４］トリアジン－５（４ｈ）－アセトアミド |
| WO2021209539A1 (en) | 2020-04-15 | 2021-10-21 | Janssen Pharmaceutica Nv | Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| WO2021214284A1 (en) | 2020-04-23 | 2021-10-28 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| US20230183249A1 (en) | 2020-04-30 | 2023-06-15 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| EP4157823A1 (en) | 2020-05-28 | 2023-04-05 | JANSSEN Pharmaceutica NV | Compounds |
| KR20230028425A (ko) | 2020-06-19 | 2023-02-28 | 에이씨 이뮨 에스에이 | Nlrp3 인플라마좀 경로를 조절하는 디하이드로옥사졸 및 티오우레아 또는 우레아 유도체 |
| IL300289A (en) * | 2020-08-14 | 2023-04-01 | Denali Therapeutics Inc | Compounds, preparations and methods |
| CN116194445A (zh) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| CN114478537B (zh) * | 2020-11-13 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 环酰胺并环化合物及其医药用途 |
| JP2024508017A (ja) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３を調節する４－アルコキシ－６－オキソ－ピリダジン誘導体 |
| WO2022184843A1 (en) | 2021-03-04 | 2022-09-09 | Janssen Pharmaceutica Nv | 4-amino-6-oxo-pyridazine derivatives modulating nlrp3 |
| CN113230240B (zh) * | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-二苯基丙-2-烯-1-酮衍生物及其应用 |
| KR20230170692A (ko) * | 2021-04-13 | 2023-12-19 | 유니티 바이오테크놀로지, 인크. | 망막 혈관병증을 치료하는 방법 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| KR20240005696A (ko) * | 2021-04-29 | 2024-01-12 | 얀센 파마슈티카 엔브이 | Nlrp3 인플라마좀 억제제로서의 프탈라지논 유도체 |
| CA3166147A1 (en) | 2021-06-23 | 2022-12-23 | Yoda Pharmaceuticals Inc. | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |
| MX2023014891A (es) | 2021-07-01 | 2024-02-12 | Janssen Pharmaceutica Nv | 5-oxo-pirido [2,3-d]piriidazin-6(5h)-ilo acetamidas. |
| WO2023028536A1 (en) * | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023044043A1 (en) * | 2021-09-17 | 2023-03-23 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| WO2023156643A1 (en) * | 2022-02-21 | 2023-08-24 | Sanofi | Thienopyrrolotriazine compounds, their preparation and their therapeutic use |
| WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
| TW202417456A (zh) * | 2022-08-10 | 2024-05-01 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| US20240124451A1 (en) | 2022-09-23 | 2024-04-18 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009008906A2 (en) * | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| AU2010309788A1 (en) | 2009-10-20 | 2012-04-05 | Novartis Ag | Glycoside derivative and uses thereof |
| NZ627709A (en) | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| EP2603081B1 (en) | 2010-08-10 | 2016-10-05 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| BR112013030442B1 (pt) | 2011-06-10 | 2021-11-09 | Merck Patent Gmbh | Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| RU2750538C2 (ru) | 2011-11-29 | 2021-06-29 | Оно Фармасьютикал Ко., Лтд. | Гидрохлорид производного пуринона |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| SI3181567T1 (sl) | 2012-09-10 | 2019-09-30 | Principia Biopharma Inc. | Spojine pirazolopirimidina, kot inhibitorji kinaze |
| WO2014085474A1 (en) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| JO3564B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | ببتيدات وتركيبات لعلاج ضرر المفاصل |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| DK2989106T3 (en) | 2013-04-25 | 2017-03-20 | Beigene Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS |
| ES2670984T3 (es) | 2013-11-05 | 2018-06-04 | Novartis Ag | Composiciones y métodos para modular receptores X farnesoides |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| NZ719169A (en) | 2013-12-20 | 2018-08-31 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
| MA39972A (fr) | 2014-05-13 | 2015-11-19 | Choi Ha Soon | Composés et compositions d'induction de la chondrogenèse |
| ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
| TN2017000119A1 (en) | 2014-10-24 | 2018-07-04 | Bristol Myers Squibb Co | Indole carboxamides compounds useful as kinase inhibitors |
| IL252913B (en) | 2014-12-24 | 2022-06-01 | Principia Biopharma Inc | Dose of site-specific btk inhibitor |
| CN113149983B (zh) | 2015-06-03 | 2024-03-29 | 普林斯匹亚生物制药公司 | 酪氨酸激酶抑制剂 |
| US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| JP6889494B2 (ja) | 2015-10-09 | 2021-06-18 | エイシア セラピューティクス， インコーポレイテッド | ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法 |
| TWI783915B (zh) | 2015-11-04 | 2022-11-21 | 德商默克專利有限公司 | 具有ｂｔｋ抑制活性之嘧啶及吡啶化合物之用途 |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| BR112018012106B1 (pt) | 2016-01-05 | 2023-12-12 | Jiangsu Hengrui Medicine Co., Ltd | Forma cristalina i de (r)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)-3-(4- (2,6- difluorofenoxi)fenil)-1h-pirrolo[2,3-d]piridazin-7(6h)-ona, método de preparar a forma cristalina i, composição farmacêutica e uso da forma cristalina i |
| CN109071535B (zh) * | 2016-04-19 | 2021-10-08 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
| US20190231784A1 (en) | 2016-06-29 | 2019-08-01 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| US11926600B2 (en) * | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
-
2019
- 2019-07-23 PE PE2021000092A patent/PE20210406A1/es unknown
- 2019-07-23 JO JOP/2021/0017A patent/JOP20210017A1/ar unknown
- 2019-07-23 SG SG11202012321PA patent/SG11202012321PA/en unknown
- 2019-07-23 US US17/259,252 patent/US20210308140A1/en active Pending
- 2019-07-23 EP EP19769892.1A patent/EP3827008B1/en active Active
- 2019-07-23 MA MA053388A patent/MA53388A/fr unknown
- 2019-07-23 CN CN201980047047.4A patent/CN112424207B/zh active Active
- 2019-07-23 KR KR1020217001895A patent/KR20210038877A/ko unknown
- 2019-07-23 CA CA3103943A patent/CA3103943A1/en active Pending
- 2019-07-23 WO PCT/IB2019/056278 patent/WO2020021447A1/en active Application Filing
- 2019-07-23 BR BR112021000964-7A patent/BR112021000964A2/pt not_active Application Discontinuation
- 2019-07-23 CU CU2021000009A patent/CU20210009A7/es unknown
- 2019-07-23 CR CR20210045A patent/CR20210045A/es unknown
- 2019-07-23 AU AU2019309727A patent/AU2019309727B2/en not_active Ceased
- 2019-07-23 MX MX2021000925A patent/MX2021000925A/es unknown
- 2019-07-23 JP JP2021503752A patent/JP2021532124A/ja active Pending
-
2021
- 2021-01-21 PH PH12021550166A patent/PH12021550166A1/en unknown
- 2021-01-21 IL IL280336A patent/IL280336A/en unknown
- 2021-01-22 CL CL2021000191A patent/CL2021000191A1/es unknown
- 2021-01-22 DO DO2021000019A patent/DOP2021000019A/es unknown
- 2021-01-22 CO CONC2021/0000537A patent/CO2021000537A2/es unknown
- 2021-01-22 EC ECSENADI20214787A patent/ECSP21004787A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112424207A (zh) | 2021-02-26 |
| IL280336A (en) | 2021-03-01 |
| WO2020021447A1 (en) | 2020-01-30 |
| US20210308140A1 (en) | 2021-10-07 |
| EP3827008A1 (en) | 2021-06-02 |
| CL2021000191A1 (es) | 2021-08-20 |
| MX2021000925A (es) | 2021-03-31 |
| JP2021532124A (ja) | 2021-11-25 |
| CA3103943A1 (en) | 2020-01-30 |
| CN112424207B (zh) | 2024-03-19 |
| CO2021000537A2 (es) | 2021-01-29 |
| BR112021000964A2 (pt) | 2021-04-20 |
| EP3827008B1 (en) | 2024-07-31 |
| KR20210038877A (ko) | 2021-04-08 |
| DOP2021000019A (es) | 2021-02-15 |
| PH12021550166A1 (en) | 2021-09-13 |
| CU20210009A7 (es) | 2021-08-06 |
| JOP20210017A1 (ar) | 2021-01-21 |
| AU2019309727B2 (en) | 2021-12-23 |
| AU2019309727A1 (en) | 2021-01-07 |
| CR20210045A (es) | 2021-06-18 |
| SG11202012321PA (en) | 2021-02-25 |
| ECSP21004787A (es) | 2021-03-31 |
| PE20210406A1 (es) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| IL287042A (en) | Inflammatory inhibitors of nlrp3 | |
| DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| DK3661921T3 (da) | Selektive hæmmere af nlrp3-inflammasom | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA44991A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| DK3442973T3 (da) | Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA53239A (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| JP2018172409A5 (ja) | １５−ｈｅｐｅを含む組成物および同組成物を使用する方法 | |
| EA201792255A1 (ru) | Ингибиторы деацетилаз гистонов и композиции и способы их применения | |
| ES2977656T3 (es) | Inhibidores de KDM1A para el tratamiento de enfermedades | |
| DK3746446T3 (da) | PRC2-inhibitorer | |
| DK3470409T3 (da) | Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer | |
| MA55893A (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| DK3774817T3 (da) | Bcl6-hæmmere | |
| MA47305A (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| CO2018002440A2 (es) | Compuestos útiles para inhibir ror-gamma-t |